Cargando…

Cap-Independent Translation in Hematological Malignancies

Hematological malignancies are a heterogeneous group of diseases deriving from blood cells progenitors. Although many genes involved in blood cancers contain internal ribosome entry sites (IRESes), there has been only few studies focusing on the role of cap-independent translation in leukemia and ly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horvilleur, Emilie, Wilson, Lindsay A., Bastide, Amandine, Piñeiro, David, Pöyry, Tuija A. A., Willis, Anne E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685420/ https://www.ncbi.nlm.nih.gov/pubmed/26734574 http://dx.doi.org/10.3389/fonc.2015.00293

Ejemplares similares

An improved analysis methodology for translational profiling by microarray
por: Sbarrato, Thomas, et al.
Publicado: (2017)

Cap-Independent Translational Control of Carcinogenesis
por: Walters, Beth, et al.
Publicado: (2016)

Design of nucleotide-mimetic and non-nucleotide inhibitors of the translation initiation factor eIF4E: Synthesis, structural and functional characterisation
por: Soukarieh, Fadi, et al.
Publicado: (2016)

RNA Binding Protein/RNA Element Interactions and the Control of Translation
por: Pichon, Xavier, et al.
Publicado: (2012)

Internal Ribosome Entry Sites Mediate Cap-Independent Translation of Bmi1 in Nasopharyngeal Carcinoma
por: Wang, Hongbo, et al.
Publicado: (2020)

A common polymorphism in the 5′ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy
por: Somers, Joanna, et al.
Publicado: (2015)

Editorial: COVID-19 and hematological malignancies: Volume II
por: Wilde, Lindsay, et al.
Publicado: (2022)

A perspective on mammalian upstream open reading frame function
por: Somers, Joanna, et al.
Publicado: (2013)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
por: Hellmich, Charlotte, et al.
Publicado: (2020)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

WNT Signaling in Hematological Malignancies
por: Frenquelli, Michela, et al.
Publicado: (2020)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

COVID-19 in Patients With Hematologic Malignancies: A Single Center Retrospective Study
por: Wang, Xuejun Alice, et al.
Publicado: (2021)

Multiple Roles of Glycans in Hematological Malignancies
por: Pang, Xingchen, et al.
Publicado: (2018)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Editorial: Epidemiological trends in hematological malignancies
por: de Lima, Marcos, et al.
Publicado: (2023)

Cap-Independent Circular mRNA Translation Efficiency
por: Deviatkin, Andrei A., et al.
Publicado: (2023)

Editorial: Rising Stars in Hematologic Malignancies 2021
por: Qian, Liren, et al.
Publicado: (2022)

Single-Cell Metabolomics in Hematopoiesis and Hematological Malignancies
por: Zuo, Fengli, et al.
Publicado: (2022)

Arginase: Mechanisms and Clinical Application in Hematologic Malignancy
por: Du, Zefan, et al.
Publicado: (2022)

Advances in the Study of circRNAs in Hematological Malignancies
por: Du, Jingyi, et al.
Publicado: (2022)

Editorial: Linking cellular metabolism to hematological malignancies
por: He, Xiujing, et al.
Publicado: (2022)

Editorial: Measurable residual disease in hematologic malignancies
por: Buccisano, Francesco, et al.
Publicado: (2023)

Editorial: Tumour microenvironment heterogeneity in hematological malignancies
por: Deaglio, Silvia, et al.
Publicado: (2023)

Germline and somatic drivers in inherited hematologic malignancies
por: Zoller, Julian, et al.
Publicado: (2023)

Editorial: Case reports in hematological malignancies: 2022
por: Antar, Ahmad, et al.
Publicado: (2023)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital Technology to Optimize Care
por: Binder, Adam F., et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies
por: Ciccone, Maria, et al.
Publicado: (2015)

Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model
por: Duran-Struuck, Raimon, et al.
Publicado: (2019)

Crosstalk Between MYC and lncRNAs in Hematological Malignancies
por: Arman, Kaifee, et al.
Publicado: (2020)

Screening Strategies for COVID-19 in Patients With Hematologic Malignancies
por: Assi, Tarek, et al.
Publicado: (2020)

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies
por: Zhao, Yan, et al.
Publicado: (2021)

The Role of Exosomes in the Progression and Therapeutic Resistance of Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2022)

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies
por: Xie, Yutong, et al.
Publicado: (2022)

Liquid biopsy in hematological malignancies: current and future applications
por: Talotta, Donatella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gsud6qoqgnqmd70u2j7sqqqs2v